Novo Nordisk A/S revealed encouraging efficacy data for a novel oral obesity medicine during a capital market day on 7 March, intriguing investors who are aware the company will need to deliver next-generation advances in obesity to maintain its leadership position in the competitive therapeutic area.
Key Takeaways
- Novo Nordisk revealed encouraging efficacy data for a novel oral obesity medicine amycretin during a capital market day.
Amycretin, which is a co-agonist of the GLP-1 and amylin receptors, could be a complementary mode of action to Novo...